Compare stocks

Molecular Partners AG is a biotechnology company specializing in the development of targeted protein therapeutics known as DARPin® molecules. These molecules are designed to modulate protein-protein interactions, providing potential treatments for a range of diseases, including cancer, ophthalmology, and infectious diseases. Founded in 2004, the company is headquartered in Zurich, Switzerland. Molecular Partners emphasizes its proprietary DARPin® technology as a competitive strength, offering advantages in selectivity and versatility compared to traditional antibodies. Its strategic focus includes advancing its pipeline of drug candidates through clinical trials and collaborating with major pharmaceutical firms for development and commercialization.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.